iwAL 2018 Session VII

 

Immunotherapy for AML & ALL

Immunotherapy was a key topic at iwAL 2018, prompting interesting debates among delegates. Presenters Farhad Ravandi, MD, Roland Walter, MD, PhD, Daniel DeAngelo, MD, PhD, Naval Daver, MD, Noelle Frey, MD, and John DiPersio, MD, PhD, covered a range of subjects in this area, including antibody therapies, checkpoint inhibitors and CAR T-cell therapy.

Presentations
Antibody Treatment Development in AML: CD123 x CD3
Farhad Ravandi, MD
University of Texas MD Anderson Cancer Center, Houston, TX
11 February, 2018

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, talks about developments in antibody treatments for AML.

Antibody-Drug Conjugates – Gemtuzumab Ozogamicin
Roland Walter, MD, PhD
Fred Hutchinson Cancer Research Center, Seattle, WA
11 February, 2018

Roland Walter, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses gemtuzumab ozogamicin.

Targeting CD22+ ALL – Inotuzumab Ozogamicin
Daniel DeAngelo, MD, PhD
Dana-Farber Cancer Institute, Boston, MA
11 February, 2018

Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, presents a talk on targeting CD22+ ALL.

Immune Checkpoint Inhibitors
Naval Daver, MD
University of Texas MD Anderson Cancer Center, Houston, TX
11 February, 2018

Naval Daver, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, outlines immune checkpoint inhibitors in AML and MDS.

CAR T-Cell Therapy in B-Cell ALL
Noelle Frey, MD
University of Pennsylvania, Philadelphia, PA
11 February, 2018

Noelle Frey, MD, from the University of Pennsylvania, Philadelphia, PA, gives a talk on CAR T-cell therapy in B-cell ALL.

Targeting T-Cell Malignancies with CAR T-cells
John DiPersio, MD, PhD
Washington University School of Medicine, Washington, WA
11 February, 2018

John DiPersio, MD, PhD, from Washington University School of Medicine, Washington, WA gives an overview of targeting T-cell malignancies with CAR T-cell therapy.